Pulmonary Hypertension

Chronic obstructive pulmonary disease: diagnosis and management: summary of updated NICE guidance - The BMJ Chronic obstructive pulmonary disease: diagnosis and management: summary of updated NICE guidance - The BMJ Posted: 29 Jul 2019 03:22 AM PDT Nicholas S Hopkinson , reader in respiratory medicine and honorary consultant physician 1 , Andrew Molyneux , consultant physician in respiratory and medicine and chair of Guideline Committee 2 , Joshua Pink , technical advisor 3 , Marie C Harrisingh , senior technical analyst 3 on behalf of the Guideline Committee (GC) 1 National Heart and Lung Institute, Imperial College, London, UK 2 Sherwood Forest Hospitals NHS Foundation Trust, Nottinghamshire, UK 3 National Institute for Health and Care Excellence, London, UK Correspondence to M Harrisingh marie.harrisingh{at}nice.org.uk What you need to know The interventions of highest value for people with chronic ob...

Cypress teen gets her wish to meet Shawn Mendes - Midland Reporter-Telegram Cypress teen gets her wish to meet Shawn Mendes - Midland Reporter-Telegram Posted: 31 Jul 2019 09:38 AM PDT Exercise Tolerance in PAH Increased With Thrice-Daily Oral Treprostinil - The Cardiology Advisor Posted: 26 Jul 2019 04:00 AM PDT Thrice-daily dosing of oral treprostinil in pulmonary arterial hypertension (PAH) has been linked with higher drug trough levels and better long-term tolerability, according to research published in Pulmonary Circulation . Researchers conducted an open-label extension study (FREEDOM-EXT; ClinicalTrials.gov identifier: NCT01027949 ) of participants who completed the phase 2 or phase 3 parent studies (ClinicalTrials.gov identifier: NCT01104870 , NCT01477333 , NCT01588405 , NCT00325442 , NCT00887978 , and NCT00325403 ) to examine the safety and efficacy of thrice-daily oral treprostinil in patien...

Better Risk Assessment Needed to Improve Clinical Care in PAH, Survey Says - Pulmonary Hypertension News Better Risk Assessment Needed to Improve Clinical Care in PAH, Survey Says - Pulmonary Hypertension News Posted: 31 Jul 2019 06:00 AM PDT While physicians worldwide are conducting multi-parametric risk assessments to evaluate pulmonary arterial hypertension (PAH), they are not doing so to the extent recommended by current guidelines, results from an international survey show. The survey found that PAH evaluations in clinical practice were not performed to the levels recommended by the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). These findings were reported in the study " Assessment of Risk of Disease Progression in Pulmonary Arterial Hypertension: Insights from an International Survey of Clinical Practice, " published in the journal Advances in Therapy . ...

Pulmonary Arterial Hypertension in Women: New Approaches to Care - The Cardiology Advisor Pulmonary Arterial Hypertension in Women: New Approaches to Care - The Cardiology Advisor Posted: 30 Jul 2019 05:00 AM PDT Pulmonary arterial hypertension (PAH), characterized by elevated blood pressure in the pulmonary artery, is a rare condition that disproportionately affects women. Over the last decade, a greater awareness surrounding PAH has led to the development of international registries of patients with PAH and improved therapies. Renewed focus on the impact of PAH in women — along with evidence that links estrogen with the activity of PAH genetic factors — has led to updated, gender-based definitions regarding the classification, pathophysiology, diagnosis, and treatment of PAH. PAH Predominately Affects Women, But Women Have Superior Survival Rates Current classification systems group different types of pulmonary hypertension (PH) accord...

Better Risk Assessment Needed to Improve Clinical Care in PAH, Survey Says - Pulmonary Hypertension News Better Risk Assessment Needed to Improve Clinical Care in PAH, Survey Says - Pulmonary Hypertension News Posted: 31 Jul 2019 06:00 AM PDT While physicians worldwide are conducting multi-parametric risk assessments to evaluate pulmonary arterial hypertension (PAH), they are not doing so to the extent recommended by current guidelines, results from an international survey show. The survey found that PAH evaluations in clinical practice were not performed to the levels recommended by the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). These findings were reported in the study " Assessment of Risk of Disease Progression in Pulmonary Arterial Hypertension: Insights from an International Survey of Clinical Practice, " published in the journal Advances in Therapy . ...

Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor Posted: 11 Jul 2019 12:00 AM PDT For patients with severe hypoxemia with pulmonary hypertension or right heart dysfunction, inhaled epoprostenol through high-flow nasal cannula increases oxygenation, according to a study published in Pharmaceutics . The researchers of this retrospective study assessed the effect of inhaled epoprostenol using a high-flow nasal cannula on oxygenation and future mechanical ventilation in patients with hypoxemia comorbid with pulmonary hypertension or right heart dysfunction in an intensive care unit setting. A chart review was completed on adult patients who were admitted into the respiratory care department of the Rush University Medical Center for severe hypoxemia between July 2015 and April 2018 and treated with inha...

Updated PAH Treatment Guidelines Released by CHEST - Pulmonary Hypertension News Updated PAH Treatment Guidelines Released by CHEST - Pulmonary Hypertension News Posted: 13 Feb 2019 12:00 AM PST An updated guideline with new recommendations for the treatment of patients with pulmonary arterial hypertension  (PAH) was released by the American College of Chest Physicians  (CHEST). The free guide, titled " Therapy for Pulmonary Arterial Hypertension in Adults 2018: Update of the CHEST Guideline and Expert Panel Report , " was published in the journal Chest . PAH is a progressive lung disorder caused by increased pressure in the lung blood vessels. Available treatment options for the disease help alleviate the pressure, reduce inflammation, and improve blood flow. Therapeutic guidelines help clinicians make informed decisions about the appropriate treatment for patients with PAH. The latest update is...

Better Risk Assessment Needed to Improve Clinical Care in PAH, Survey Says - Pulmonary Hypertension News Better Risk Assessment Needed to Improve Clinical Care in PAH, Survey Says - Pulmonary Hypertension News Pulmonary Arterial Pressure Above 30 mmHg Linked to Increased Mortality - Pulmonary Hypertension News Inoperable Chronic Thromboembolic Pulmonary Hypertension: BPA vs Riociguat - Pulmonology Advisor Better Risk Assessment Needed to Improve Clinical Care in PAH, Survey Says - Pulmonary Hypertension News Posted: 31 Jul 2019 06:00 AM PDT While physicians worldwide are conducting multi-parametric risk assessments to evaluate pulmonary arterial hypertension (PAH), they are not doing so to the extent recommended by current guidelines, results from an international survey show. The survey found that PAH evaluations in clinical practice were not performed to the levels recommended by the European So...